NOV 18, 2020 6:30 AM PST

Nerve Damage as a Prognostic Marker for Rare Autoimmune Disease

WRITTEN BY: Tara Fernandez

Researchers have identified a new prognostic biomarker for Guillain-Barré syndrome (GBS), a rare autoimmune disorder that attacks the nerves and can eventually paralyze the entire body. The biomarker, neurofilament light chain, or NfL, signals the presence of axonal damage. As published in the Journal of Neurology, Neurosurgery, and Psychiatry, high circulating levels of NfL in GBS patients were found to be associated with more severe disabilities.

These findings significantly impact the clinical strategies for managing GBS and increase neurologists' understanding of the physiological processes underlying this devastating disease.

"First, they confirm that residual long-term disability in GBS is clearly associated to the degree of axonal damage that happens at the onset of the disease," said Luis Querol, senior author of the study.

"They also suggest that serum NfL could be used to stratify patients at admission, and in the future, select patients who may be candidates for more aggressive therapies or those who may have good prognosis independently of the apparent severity they have at onset," said Querol.

The root causes of GBS continue to mystify scientists, although a large proportion of patients report having a severe respiratory or gastrointestinal infection in the leadup to the disease. Among the early signs of GBS are a prickling sensation in the fingers, limb weakness, and double vision.

Measuring the degeneration of axons, or nerve fibers, can determine a GBS patient’s outcomes and shape clinical interventions moving forward, said Bart Jacobs from the Erasmus Medical Center in Rotterdam. 

In an editorial on the study, Jacobs writes: "Axonal injury may occur in AMAN as well as acute inflammatory demyelinating polyneuropathy and in severe cases may result in irreversible degeneration. Treatment with immunoglobulins or plasma-exchange aims to prevent further axonal injury, but clinicians currently have no methods to monitor the response directly."

 

 

Sources: MedPage Today, Journal of Neurology, Neurosurgery & Psychiatry.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 15, 2020
Cardiology
Following Platelets to Diagnose Myocarditis
AUG 15, 2020
Following Platelets to Diagnose Myocarditis
The heart is a sensitive thing, prone not just to metaphorical heartbreak, but genuine issues if not taken care of. Myoc ...
AUG 20, 2020
Cardiology
A New Test to Discern Kawasaki Disease from Sepsis
AUG 20, 2020
A New Test to Discern Kawasaki Disease from Sepsis
Kawasaki disease is a rare cardiovascular disease affecting children under the age of five. If untreated, there is a cha ...
SEP 02, 2020
Cancer
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
SEP 02, 2020
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
For many rare diseases, there is a lack of a “standard” treatment options. This is more prevalent in diverse ...
OCT 05, 2020
Cancer
Does Having an Appendectomy Increase Your Risk for Cancer?
OCT 05, 2020
Does Having an Appendectomy Increase Your Risk for Cancer?
Cancer research is more than just the study of diagnostics and novel therapies. Researchers also investigate the causes ...
NOV 03, 2020
Genetics & Genomics
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
NOV 03, 2020
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
Genetic sequencing technologies have rapidly advanced, reducing the time required to sequence the entire human genome fr ...
NOV 26, 2020
Clinical & Molecular DX
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
NOV 26, 2020
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
New research has revealed that exposure to radiation from diagnostic procedures such as X-rays could contribute to an el ...
Loading Comments...